BIOCRYST PHARMACEUTICALS INC (BCRX)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$173.4M
Cash & Equivalents
$61.8M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$2,656M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
PERAMIVIR
RAPIVAB |
APPROVED | Acute, Uncomplicated Human Influenza, Arthritis, B-cell Acute Lymphoblastic Leukemia, Cancer, Chronic Lymphocytic Leukemia (CLL), Complement 3 Glomerulopathy, Cough, COVID-19, Cutaneous T-cell Lymphoma (CTCL),, Diabetic Macular Edema (DME), Ebola Virus Infection, Fatigue, Fever, Filovirus Infections, Gout, HAE, Headache, Hereditary Angioedema, Hereditary Angioedema (HAE), HIV Infections, Hyperuricemia, Immunoglobulin A Nephropathy, Influenza, Joint Disease, Leukemia, Leukemia, Lymphocytic, Leukemia, Lymphocytic, Chronic, Leukemia, T-Cell, Lymphoma, Marburg Virus Disease, Membranous Nephropathy, Myalgia, Nasal Congestion, Netherton Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), Pediatric, PNH, Prophylaxis, Renal Failure, Renal Insufficiency, Seasonal Influenza, Sore Throat, Yellow Fever |
|
BEROTRALSTAT DIHYDROCHLORIDE
ORLADEYO |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-01 | Phase1 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06842823 | A Study of Navenibart in Participants With Hereditary Angioedema | PHASE3 | Active Not Recruiting | 157 |
| NCT06539507 | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 | PHASE1 | Recruiting | 78 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-29 | 8-K | BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796) - PRESS RELEASE | EDGAR |